Global Precision Medicine Market is expected to foresee a significant growth during the forecast. United States to witness highest growth

Global Precision Medicine Market is expected to reach the market valuation of US$ 105.64 billion by 2026 expanding at a reasonable CAGR of 9.95% during the forecast period (2021-2026) from US$ 58.66 billion in 2019. Development in precision medicine is occurring at an owing to the effectiveness of this medication. Government bodies such as research institutes and hospitals are also taking part for its development.

For a detailed analysis of the Precision Medicines browse through

Healthcare is changing rapidly. Several technologies are being introduced every year to decrease the mortality rate. Currently, a transition has been witnessed from the traditional reactive medicine that was based on symptoms, diagnosis and treatment to a system that targets the disease much earlier it occurs. Precision Medicine is that new way of thinking. The major principles on which the precision medicine is based involves prediction, prevention, personalization, and participation. The growing attention toward precision medicine is directed by a fundamental shift from the ‘one size fits all’ paradigm for treatment of patients with conditions or predisposition to diseases. Driven by these, numerous national as well as international genome projects have been initiated to reap the benefits of precision medicine.

For a detailed analysis of the regulations in Precision Medicines browse through

According to an analysis, the topmost 10 highest-grossing drugs in the U.S. merely help between 1 in 4 to 1 in 25 of the patients who administer them. This estimate highlights the lack of specificity for the drugs that are in currently in use and provides the opportunity that exists for highly targeted precision medicines. Gene sequencing is a major part of precision medicine as it is genome based. Advances in next generation sequencing (NGS) technologies have resulted in an exceptional proliferation and surge of genomic sequence data.

For a detailed analysis of the initiatives in Precision Medicines browse through

Precision medicine is not only based on pharmacology. There are numerous components of this type of medicine as they are highly specific to the genome of a group of individuals. Big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others are some of the technologies that are required for the precision medicine development. Bioinformatics and gene sequencing are required for producing genomic data, as genomic data is necessary for the drug development. Big data analytics is used for the analysis of the data produced. Oncology, respiratory diseases, central nervous system disorders, immunology and genetic diseases are some of the mostly studied diseases in this area. More than 50% of the precision medicine research is done on oncology, as it is one of the burning topics in healthcare.

For a detailed analysis of the automation in Precision Medicines browse through

There are several end-users of precision medicine. hospitals & clinics, pharmaceuticals, diagnostic companies, Healthcare-IT firms, and others are some of the major end users. Pharmaceutical companies are developing precision medicine by collaborating with several players. Amgen, a leading biotechnology company and Syapse announced a precision medicine collaboration in oncology. These collaborations act as the ‘X factor’ for the thriving industry. Genomic sequencing also plays a crucial part in precision medicine development as genomic sequencing and biomedical informatics in the laboratory plays an important role in reporting and decision support to the patients.

Request for Sample of the report browse through

Additionally, the report provides detailed initiatives that are being taken in the field of precision medicine. The market is classified into distinct regions including North America (U.S and Canada), Europe (Germany, France, Spain, Italy, and United Kingdom), Asia-Pacific (China, Japan, India, and Australia) and rest of the world. United States generated revenue of US$ 17.9 billion in 2019. However, APAC region is expected to witness the highest CAGR growth of 11.27% during the forecast period 2020-2026.

Hoffmann-La Roche, Eli Lilly and Company, NeoGenomics Laboratories, Novartis, Teva Pharmaceutical, Thermo Fisher Scientific, Quest Diagnostics, Abbott Laboratories, NanoString Technologies, and AstraZeneca are some of the prominent players operating in the global precision medicine market. Several M&A’s along with partnerships have been undertaken by these players to develop precision medicine.

Global Precision Medicine Market Segmentation

Market Insight, by Technology Type

  • Big Data Analytics
  • Bioinformatics
  • Gene Sequencing
  • Drug Discovery
  • Companion Diagnostics
  • Other Products

 Market Insight, by Application

  • Oncology
  • Respiratory Diseases
  • Central Nervous System Disorder
  • Immunology
  • Genetic Diseases
  • Others

Market Insight, by End-User

  • Hospitals & Clinics
  • Pharmaceuticals
  • Diagnostic Companies
  • Healthcare-IT Firms
  • Others

   Market Insight, by Region

  • North America
    • United States
    • Canada
    • Rest of North America
  • Europe
    • Italy
    • Spain
    • France
    • Germany
    • United Kingdom
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Rest of World

Top Company Profiles

  • Hoffmann-La Roche
  • Medtronic
  • Qiagen
  • Illumina
  • Abbott Laboratories
  • GE Healthcare
  • NanoString Technologies
  • BioMérieux SA
  • Danaher Corporation
  • AstraZeneca